Renal protection with angiotensin receptor blockers: where do we stand

2011 ◽  
Vol 24 (5) ◽  
pp. 569-580 ◽  
Author(s):  
Roland E. Schmieder ◽  
Luis-Miguel Ruilope ◽  
Anthony H. Barnett
Keyword(s):  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Renal Protection ◽  
Receptor Blockers

Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence

2010 ◽  
Vol 120 (8) ◽  
pp. 307-319 ◽  
Author(s):  
Lauren M. Willis ◽  
Azza B. El-Remessy ◽  
Payaningal R. Somanath ◽  
David L. Deremer ◽  
Susan C. Fagan
Keyword(s):  
Molecular Mechanisms ◽  
Science Studies ◽  
Angiotensin Receptor Blockers ◽  
Vascular Density ◽  
Angiotensin Receptor ◽  
Renal Protection ◽  
Converting Enzyme Inhibitors ◽  
Cellular Models ◽  
Published Evidence ◽  
Receptor Blockers

Angiotensin II type 1 receptor antagonists [ARBs (angiotensin receptor blockers)] are indicated for BP (blood pressure)-lowering, renal protection and cardioprotection in patients unable to tolerate ACEIs (angiotensin-converting enzyme inhibitors). A recent meta-analysis revealed an association between ARBs and tumour development, possibly due to enhancement of angiogenesis. However, published evidence is conflicting on the effects of ARBs on angiogenesis or the expansion of the existing vascular network. ARBs have been shown to exert primarily anti-angiogenic effects in basic science studies of cancer, retinopathy, peripheral artery disease and some models of cardiovascular disease. In animal and cellular models of myocardial infarction and stroke, however, ARB administration has been associated with robust increases in vascular density and improved recovery. The aim of the present review is to examine the angiogenic effects of ARBs in animal and cellular models of relevant disease states, including proposed molecular mechanisms of action of ARBs and the clinical consequences of ARB use.

Angiotensin-receptor blockers for renal protection in Type 2 diabetes

Aging Health ◽  
2006 ◽  
Vol 2 (2) ◽  
pp. 295-301
Author(s):  
Piero Ruggenenti ◽  
Manuel Macia ◽  
Giuseppe Remuzzi
Keyword(s):  
Type 2 Diabetes ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Renal Protection ◽  
Receptor Blockers

Amlodipine versus Angiotensin-Receptor Blockers for Nonhypertension Indications

2002 ◽  
Vol 36 (11) ◽  
pp. 1759-1766
Author(s):  
James S Kalus ◽  
C Michael White
Keyword(s):  
Heart Failure ◽  
English Language ◽  
Data Extraction ◽  
Angiotensin Receptor Blockers ◽  
Safety Data ◽  
Concomitant Disease ◽  
Angiotensin Receptor ◽  
Renal Protection ◽  
Medline Search ◽  
Receptor Blockers

OBJECTIVE: To review the efficacy and safety data of amlodipine and the angiotensin-receptor blockers (ARBs), focusing on heart failure, angina, percutaneous coronary intervention (PCI), and renal protection. DATA SOURCE: A MEDLINE search (1966–December 2001) was completed using amlodipine, angiotensin-receptor antagonist, losartan, valsartan, candesartan, and telmisartan as key words. English-language articles were identified and included. STUDY SELECTION AND DATA EXTRACTION: All identified articles were evaluated. Articles representative of the subject matter of our review were included. DATA SYNTHESIS: Amlodipine and the ARBs lower blood pressure to a similar extent. Amlodipine is an effective antianginal agent, whereas ARBs are not. However, amlodipine is not effective in the treatment of heart failure; ARBs may be useful in this setting. ARBs are also effective in preserving renal function and may provide some protection from restenosis in patients who have had a PCI. The ARBs may also be useful in preventing both diabetic and nondiabetic nephropathy. CONCLUSIONS: Concomitant disease states should be considered when choosing between an ARB and amlodipine for the management of hypertension.

Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450

2016 ◽  
Vol 17 (7) ◽  
pp. 681-691 ◽  
Author(s):  
Ruirui Yang ◽  
Zhiqiang Luo ◽  
Yang Liu ◽  
Mohan Sun ◽  
Ling Zheng ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cytochromes P450 ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers
Sign in / Sign up

Export Citation Format

Share Document